Beta2-agonists: Friend or foe?

Jean G. Ford, Javed Iqbal, Yisa Sunmonu

Research output: Contribution to journalArticle

Abstract

This review summarizes the effects of beta2-agonists on asthma severity. There has been a controversy as to whether the regularly scheduled use of beta2-adrenergic agonists increases the risk of adverse outcomes in asthma. A number of epidemiological and clinical studies have found an association between the regularly scheduled use of beta-agonist drugs and increased risk of asthma morbidity and mortality. However, this observation has not been consistent across studies. We discuss here the potential mechanisms to explain the relationship between the use of beta-agonists on a regularly scheduled basis and adverse outcomes of asthma therapy; and we provide a brief review of the effect of genetic diversity at the beta2-adrenergic receptor locus on asthma severity. Overall, the evidence suggests that the beta2-agonists in current use in the United States are generally safe and effective; friends, not foes.

Original languageEnglish (US)
Pages (from-to)369-375
Number of pages7
JournalSeminars in Respiratory and Critical Care Medicine
Volume23
Issue number4
DOIs
StatePublished - Aug 2002

Fingerprint

Asthma
Adrenergic beta-2 Receptor Agonists
Adrenergic Receptors
Epidemiologic Studies
Morbidity
Mortality
Pharmaceutical Preparations
Therapeutics

Keywords

  • Asthma
  • Beta2-adrenergic agonists
  • Genetics
  • Pharmacological
  • Receptors

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Pulmonary and Respiratory Medicine
  • Critical Care

Cite this

Beta2-agonists : Friend or foe? / Ford, Jean G.; Iqbal, Javed; Sunmonu, Yisa.

In: Seminars in Respiratory and Critical Care Medicine, Vol. 23, No. 4, 08.2002, p. 369-375.

Research output: Contribution to journalArticle

Ford, Jean G. ; Iqbal, Javed ; Sunmonu, Yisa. / Beta2-agonists : Friend or foe?. In: Seminars in Respiratory and Critical Care Medicine. 2002 ; Vol. 23, No. 4. pp. 369-375.
@article{6aa602abafb7421da32e90351fbc2b69,
title = "Beta2-agonists: Friend or foe?",
abstract = "This review summarizes the effects of beta2-agonists on asthma severity. There has been a controversy as to whether the regularly scheduled use of beta2-adrenergic agonists increases the risk of adverse outcomes in asthma. A number of epidemiological and clinical studies have found an association between the regularly scheduled use of beta-agonist drugs and increased risk of asthma morbidity and mortality. However, this observation has not been consistent across studies. We discuss here the potential mechanisms to explain the relationship between the use of beta-agonists on a regularly scheduled basis and adverse outcomes of asthma therapy; and we provide a brief review of the effect of genetic diversity at the beta2-adrenergic receptor locus on asthma severity. Overall, the evidence suggests that the beta2-agonists in current use in the United States are generally safe and effective; friends, not foes.",
keywords = "Asthma, Beta2-adrenergic agonists, Genetics, Pharmacological, Receptors",
author = "Ford, {Jean G.} and Javed Iqbal and Yisa Sunmonu",
year = "2002",
month = "8",
doi = "10.1055/s-2002-34332",
language = "English (US)",
volume = "23",
pages = "369--375",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Beta2-agonists

T2 - Friend or foe?

AU - Ford, Jean G.

AU - Iqbal, Javed

AU - Sunmonu, Yisa

PY - 2002/8

Y1 - 2002/8

N2 - This review summarizes the effects of beta2-agonists on asthma severity. There has been a controversy as to whether the regularly scheduled use of beta2-adrenergic agonists increases the risk of adverse outcomes in asthma. A number of epidemiological and clinical studies have found an association between the regularly scheduled use of beta-agonist drugs and increased risk of asthma morbidity and mortality. However, this observation has not been consistent across studies. We discuss here the potential mechanisms to explain the relationship between the use of beta-agonists on a regularly scheduled basis and adverse outcomes of asthma therapy; and we provide a brief review of the effect of genetic diversity at the beta2-adrenergic receptor locus on asthma severity. Overall, the evidence suggests that the beta2-agonists in current use in the United States are generally safe and effective; friends, not foes.

AB - This review summarizes the effects of beta2-agonists on asthma severity. There has been a controversy as to whether the regularly scheduled use of beta2-adrenergic agonists increases the risk of adverse outcomes in asthma. A number of epidemiological and clinical studies have found an association between the regularly scheduled use of beta-agonist drugs and increased risk of asthma morbidity and mortality. However, this observation has not been consistent across studies. We discuss here the potential mechanisms to explain the relationship between the use of beta-agonists on a regularly scheduled basis and adverse outcomes of asthma therapy; and we provide a brief review of the effect of genetic diversity at the beta2-adrenergic receptor locus on asthma severity. Overall, the evidence suggests that the beta2-agonists in current use in the United States are generally safe and effective; friends, not foes.

KW - Asthma

KW - Beta2-adrenergic agonists

KW - Genetics

KW - Pharmacological

KW - Receptors

UR - http://www.scopus.com/inward/record.url?scp=0036686592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036686592&partnerID=8YFLogxK

U2 - 10.1055/s-2002-34332

DO - 10.1055/s-2002-34332

M3 - Article

C2 - 16088630

AN - SCOPUS:0036686592

VL - 23

SP - 369

EP - 375

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - 4

ER -